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1. Introduction
In the same way that Watson and Crick’s breakthrough in identifying the molecular structure
of the DNA double helix revolutionized the last sixty years of molecular biology, the field of
epigenetics is set to do the same for the next sixty (or more) years! An alphabet of four letters,
and strict guidelines dictating their arrangement, comprise the genome of all known living
organisms. This same system has allowed us to unravel many of the secrets to human health
and to comprehend a great number of once-elusive conditions and diseases. Nevertheless, a
vast number of puzzles remain to be solved, and the genetic code is but one tool used to make
sense of them.
Our understanding of our genetics has grown enormously over the last several decades and
the iconic image of the DNA double helix has become a cornerstone for the field. Most certainly,
the information contained within this static DNA code is but a starting point. Yet, a number
of seemingly straightforward questions cannot be answered without going beyond the highly
conserved script. Undoubtedly, many ask: Why and how is an endothelial cell different from
a brain cell when the static DNA genome is identical? To answer this and many other complex
and fascinating phenomena, we must, instead, go over or above (epi-) genetics because the
DNA blueprint is identical in each of the abovementioned somatic cells. A term coined in the
1940s by Conrad Waddington, epigenetics refers to chromatin-based mechanisms important
in the regulation of gene expression that do not involve changes to the DNA sequence per se.
Epigenetic principles, in eukaryotic organisms, are linked by an important common thread:
DNA does not exist in a “naked” state. Figure 1 provides a visual representation of the added
layer of chemical species, as well as proteins which themselves can be modified – all of which
contribute to a layer of chemical complexity and significant implications that epigenetics
strives to classify and understand.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Division and differentiation are fundamental processes for sending cells of common origin to
different destinations. Logically, the timing and regulation of these processes must be de‐
pendent on more than an identical code contained in all body cells. Thus, the epigenome
comprises the ever-expanding repertoire of chemical alterations that regulate the expression
of genes and, hence, dictate the function of cells and the role of proteins. A number of genetic
determinants, as well as lineage-specific markings, and environmental responses are used to
construct the epigenome [1]. The existence of an epigenetic code is a highly contested topic [2]
and one which will be explored throughout this chapter. Indeed, it is not only mistakes in the
genetic code, but also deviations in the epigenome that may provide clues to understanding
the onset of detrimental conditions and diseases.
2. Three mechanisms of epigenetics
2.1. Posttranslational histone modifications
Compaction of the entire 6 billion base pair genome, 3 billion in each copy of the haploid
genome, into each one of 50 trillion human body cells is a truly breathtaking achievement! In
each cell, 2 meters of DNA are condensed by at least 10, 000 fold in order to fit into the roughly
6 µm diameter of the nucleus. In accomplishing this monumental feat, intricate folding and
wrapping are the first steps in organizing the DNA. Covalent and non-covalent interactions
further alter the three-dimensional arrangement of the chromatin. Chromatin refers to the state
of DNA when it is spooled around the fundamental repeat unit: the nucleosome [3]. Each
nucleosome consists of an octamer containing four different core histone units: histones H2A,
H2B, H3 and H4. Two of each core histone unit are present within one nucleosome such that
a tetramer of H3 and H4 joins two dimers of H2A and H2B [3]. At least one fifth of the amino
acids in each core protein are lysine or arginine – those with highly basic side chains [4].
Approximately 147 base pairs of DNA wrap around each nucleosome. Linker histones,
especially H1, interconnect each nucleosome. Structurally, each of the canonical histone core
proteins has a characteristic N-terminal tail of amino acids extending out from the core, which
is highly susceptible to modifications [3].
Contrary to what biologists believed for many years, kinetic experiments have shown that
DNA wrapping around a nucleosome is surprisingly dynamic. Open exposure for 10 to 50
milliseconds – the length of time between rapid winding and unwinding – means that DNA
is available for binding other proteins [5]. The formation of nucleosomes converts a DNA
molecule into thread-like chromatin approximately one-third of its initial length [4].
Since the initial work in histone acetylation and methylation by Allfrey and colleagues [6],
many other modifications have been documented, with the most frequently found to be, at
steady state, lysine acetylation, mono-, di-, and tri-methylation of lysines, and the phosphor‐
ylation of serines [7]. Concomitantly, a particular collection of enzymes is responsible for each
of these additions: histone acetyl transferases (HATs) and histone methyl transferases (HMTs).
Importantly, each of these modifications are reversible, the opposite reactions catalyzed by a
group of histone deacetylases (HDACs) and histone demethylases (HDMTs). Most often, the
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binding of DNA gene regulatory proteins, or transcription factors, is a pre-requisite for the
recruitment action of any of these enzymes. Such events occur at different times in the
developmental history of a cell and groups of nucleosomes may be modified in a multitude of
ways based on the status of the cell [4].
The mechanism by which histone posttranslational modifications (PTMs) occur can be broadly
categorized into 3 groups: a) altering chromatin structure with small (acetylation, phosphor‐
ylation, methylation) or large (ubiquitylation, sumoylation) chemical groups, b) inhibiting
binding factors to the chromatin, and c) attracting a particular set of proteins to the newly
modified regions. In the following, we will highlight the notable features of the well-studied
mechanisms and allude to the implications of them throughout the remainder of this chapter.
First, acetylation is a posttranslational histone mark that is known to be correlated with
transcriptional activation. Broadly speaking, chromatin structure is loosened by the acetylation
of lysine (denoted by K) residues. This modification allows for DNA binding sites to be made
more accessible, at the same time that a new collection of proteins are recruited to this region
of modified chromatin [8]. Positive charges at highly basic histone tails are neutralized with
lysine acetylation, which reduces the binding of the amino acid to the negatively charged DNA
[9]. An actual change of the physical properties of the histone tails, such as neutralization, is
an example of a cis-effect. In this instance, a segmental expansion of the chromatin allows for
easier access to transcriptional regulators. When other proteins are actively recruited to the
chromatin and read snippets of it, a trans-effect is said to occur. The example HPTM recruiting
new proteins was observed with histone tail acetylation. Bromodomain are specialized protein
domains, found in HATs such as Gcn5 and CBP/p300. [10, 11].
Figure 1. Three defining epigenetic mechanisms: DNA methylation, posttranslational histone modifications, and RNA-
based mechanisms. The four-lettered (adenine, cytosine, guanine, thymine) code that constitutes an individual’s ge‐
netic makeup is identical in all cell types and is highly conserved during mitotic and meiotic divisions, whereas the
three epigenetic modifications differ amongst cell types and are only partly conserved during mitosis and meiosis. In
the “Nurture vs. Nature” debate, genetics characterizes the latter with strong evolutionary convergence while epige‐
netics is influenced by the former, such that the dynamic patterns that classify it diverge rapidly through evolution.
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Histone methylation has proven to be more perplexing than histone acetylation due to the fact
that lysine can be mono-, di-, or tri-methylated and arginine can be mono-or di-methylated.
Knowing that there are 24 sites of lysine and arginine methylation on the four histone core
proteins, means that a tremendous number of methylated/unmethylated states are possible
[12-15]. Astonishingly, lysine methylation can result in either the activation or silencing of gene
expression. Generally, the methylation of lysines 4, 36, and 79 on histone H3 (H3K4me,
H3K36me, H3K79me, respectively) are correlated with transcriptional activation, while the
remainder have repressive activity [15]. Two of these marks, namely methylation on lysine 79
of histone H3 and 20 on histone H4, also play a vital role in DNA repair [15]. Arginine
methylation is similar, in that the process has been correlated with both negative and positive
transcriptional regulation in numerous contexts [16-19].
In contrast to the addition of small chemical species, other larger modifications of histones are
described (acetyl, phosphate, and methyl). Ubiquitylation and sumoylation, the addition of
ubiquitin (Ub) and small ubiquitin-like modifier (SUMO), respectively, increases the size of
the histone by up to two-thirds [20]. Depending on the site of ubiquitylation, this process can
result in either transcriptionally active or inactive segments of chromatin [21]. Currently, there
are no known ubiquitin chromatin binding proteins, but it is hypothesized that ubiquitin
protein is again likely involved in a more diverse array of interactions than are the smaller
chemical additions. Although much less well studied, SUMO is thought to recruit deacetylases
and/or block lysine substrates that could be acetylated. Both mechanisms are consistent with
results that have shown sumoylation to be correlated with transcriptional repression [20].
As a final note on PTMs, chromatin remodelling complexes that rely on the hydrolysis of ATP
are known to temporarily alter the structure of nucleosomes by reducing the attraction between
DNA and its neighbouring histone. This is commonly referred to as “nucleosome sliding” and
the action briefly makes the DNA more susceptible to the effects of other proteins [4]. This
sequence of events likely allows for a greater range of interactions of which we are not yet fully
aware. It is important to stress that chromatin structure is highly regulated by nucleosome
eviction and alternative histone core protein usage. This is a new area of study.
2.2. DNA methylation
The second major epigenetic pathway is DNA methylation - the addition of a methyl group (-
CH3) to the five position of the nitrogenous base, cytosine (Figure 1). Often referred to as the
“fifth base pair,” the product of this reaction, 5-methylcytosine (5mC), is the most common
mutagenic base in the mammalian genome. Mutation of methyl CpG to uracil pG then TpG
results in CpG depletion and TpG enrichment in the mammalian genome. DNA methylation
is predominantly observed at CpG sites in the mammalian genome, with the methyl modifi‐
cation at non-CpG dinucleotides unusual, except perhaps in stem cells and mature neurons.
Not to be confused with cytosine complementarily binding with guanine across the DNA
double helix, CpG sites refer to locations where cytosine and guanine are separated by a
phosphodiester bond, adjacent to one another. The vast majority, approximately 70-80%, of all
CpG sites in the mammalian genome are, indeed, methylated [22]. Distribution of methylation
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across the genome shows enrichment at centromeric heterochromatin, repetitive element
(transposon), and non-coding regions [23].
Unlike the great variability of histone modifications, DNA methylation is well known to be a
mark of transcriptional repression [24]. Having been the first epigenetic mechanism identified,
DNA methylation has been studied for the longest time and its consequences are well
entrenched in a variety of essential biochemical processes, abnormal conditions, and diseases.
X chromosome inactivation and imprinting are two such phenomena where normal DNA
methylation in early development plays a vital role in setting the stage for monoallelic
expression from chromosones during cellular maturation [25]. Deregulation of the methylation
mechanism can lead to Immunodeficiency Centromeric instability, and Facial abnormalities
syndrome (ICF) as well as being a contributing factor to cancer progression [26].
There are two main hypothesized mechanisms by which DNA methylation is proposed to
repress gene expression. The first of these is a physical interference with the binding of regular
transcription factors. The methyl group itself may physically project into the major groove of
the DNA double helix, whereby it interferes with the sequence-specific recruitment of DNA
proteins [27]. In support of this, a number of transcription factors have been found to recognize
GC rich regions of the genome – the very same regions that are most susceptible to CpG
methylation. Subsequently, these factors are unable to bind when methylcytosine takes the
place of cytosine. The second proposed mechanism is in opposition to the first, as proteins are
not repelled by the presence of 5mC, but are instead attracted to it. After the purification and
cloning of an individual methyl-CpG binding protein, MeCP2 [28], four more similar proteins
were identified and are now referred to as methyl-CpG binding domain proteins (MBDs). The
attraction of these MBDs has been shown to block the binding of activating transcription factors
and to actually recruit to the chromatin, histone-modifying enzymes, chromatin remodelers,
and RNA molecules [29-31]. Several such conglomerates have been proposed to co-operatively
silence gene expression [32].
2.2.1. DNA methyltransferases
The reaction that yields 5mC as its product is catalyzed by a family of three DNA methyl‐
transferases (DNMTs): DNMT1, DNMT3A and DNMT3B [33]. DNMT1, the first of three family
members, is a maintenance methyltransferase as it is responsible for transmitting methylation
patterns from one cellular generation to the next. Replication of DNA demands that the two
strands first be unwound, and it is during this time that DNMT1 is recruited to the replication
fork. Binding of proliferating cell nuclear antigen (PCNA) to both strands and UHRF1
(ubiquitin-like with PHD and RING finger domains 1) protein via its characteristic SET-and
RING-associated (SRA) domain, are pre-requisites for the recruitment of DNMT1 [34-36]. This
enzyme exhibits methylation preference for hemi-methylated DNA, that is, double stranded
DNA where only one strand exhibits methylation [37, 38]. Following replication, the parent
strand displays the necessary methylation patterns and is subsequently used as a template for
the DNMT1-mediated methyl addition to the nascent, naked strand of DNA. Such sites are
accurately methylated due to the palindromic nature of the CpG sequences and the fact that
methylation patterns between the two strands are symmetrical. Two other DNMTs include
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DNMT3A and DNMT3B, both of which have been shown to function as de novo methyltrans‐
ferases, displaying preferential methyl addition to unmethylated DNA [39]. These DNMTs
play a crucial role in embryonic development, during which time the methylation patterns to
be propagated in somatic cells are established [40].
The catalytic domain of the DNA methyltransferases is conserved amongst all of the DNMTs.
Despite this, very little similarity is seen at their N-terminal domain. The regulatory domain
of DNMT1 is composed of at least five motifs that are not present on the other enzymes,
whereas DNMT3A and 3B exhibit two unique motifs. DNMT1 motifs include: a PCNA-
interacting domain, a nuclear localization signal, a replication foci-targeting domain, a DNA-
binding CXXC region, and a protein-protein interaction motif called the bromo-adjacent
homology domain [26]. Those of DNMT3A and 3B include a motif essential for heterochro‐
matin association, PWWP [41, 42] or “pro-trp-trp-pro,” as well as a motif for protein-protein
interactions: the ATRX-related cysteine-rich region containing a zinc finger and an atypical
PHD domain [26].
2.2.2. CpG Islands
The fact that 5mC is the most common mutagenic base of the mammalian genome can be
explained by methylcytosine’s susceptibility to deamination [43, 44]. Upon deamination, the
modified nitrogenous base is replaced by thymine and a T:G mismatch is generated. Rather
than the rapid repair mechanism activated by cytosine deamination to uracil, T:G mismatches
tend to accumulate and are not readily removed. Consequently, the genome becomes CpG
depleted and TpG enriched. As indicated in Table 1, CpG islands (CGIs) are regions of the
genome that have been spared this phenomenon; the number of CpG sites observed (O) is
equivalent to the number that would be expected (E) based on C or G nucleotide abundance.
As a result, the ideal situation would be an O/E of 1.
The definition of a CpG island has undergone a great deal of revision since the earliest
studies dealing with these genomic regions [45] and are now rather arbitrarily defined as
being > 500 bp [46], but averaging around 1000 bp. The O/E range determines the strength
of a CpG island with the strongest having O/E > 0.75, a weak one with an O/E between
0.45 and 0.75, and a poor CGI having an O/E < 0.45. These regions are characterized by
their elevated C+G content with the %C+G content > 55% [46]. These segments are especially
fascinating due to their unusually low levels of DNA methylation marks. In essence, these
regions are very often observed to be unmethylated. Due to the lack of repressive flags,
genes  that  are  downstream of  CGI  containing promoters  are  often in  an active  state  of
expression. It has been speculated that practically all CGIs are transcription start sites (TSS),
largely of housekeeping and developmentally important genes [47, 48]. Approximately 70%
of all gene promoters are CGIs [49].
The relationship between structure and function is seen most vividly in many of the compo‐
sitional characteristics of CGIs. For instance, a recent study found that the CGI at the promoters
of a particular group of genes was relatively nucleosome-deficient [50]. That is, the underlying
DNA was highly accessible to activating transcription factors because less of it was spun
around nucleosomes. Evidence from additional studies has shown that this nucleosome
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deficiency is a feature of CGI promoters, in general [51-53]. It is not yet known whether this
phenomenon is a result of intrinsic chromatin instability or nucleosome exclusion due to the
presence of the transcription initiation complex. Interestingly, it was found early in the study
of CpG islands that, when found at promoter regions, these segments lack the canonical TATA
box that so many eukaryotic promoters possess [54, 55]. Constitutive binding of RNA poly‐
merase II is a frequently documented feature of CGIs. Presence of RNA polymerase II would
evidently be associated with transcriptional activation as it is the major player involved in
regular transcription.
Several histone chromatin features are also known to typify CpG islands, one of which is the
depletion of histone 3 lysine residue 36 dimethylation, H3K36me2 [56]. Even though no
conclusion has been reached as to why it is the absence of this dimethylation that characterizes
most CpG islands, the modification has been reported, in yeast, to inhibit transcriptional
initiation via histone deacetylase attraction. [57-59]. This absence makes way for the transcrip‐
tionally permissive state of CGIs. Furthermore, CGIs are marked by activating histone
acetylation; both H3 and H4 acetylation are frequently observed [51, 60]. Notably, Cfp1 (CXXC
finger protein 1) is a well characterized and fundamental component of the Setd1 H3K4
methyltransferase complex [61] and is drawn towards the overwhelming majority of CGIs in
the mouse genome [62]. In the context of CpG islands, this protein directs H3K4 trimethylation,
the activity of which has been shown to prevent DNA methylation of the underlying code [63,
64]. Hence, the DNA is maintained in a potentially active transcriptional state.
2.2.3. 5-hydroxymethylcytosine: the 6th base pair
The long-standing study of DNA methylation took a significant turn in 2009 with the redis‐
covery of what is now commonly referred to as the “6th base pair:” 5-hydroxymethylcytosine
(5hmC) [65]. This base is the product of an enzymatic reaction that adds a hydroxyl (-OH)
group to the methyl of 5-methylcytosine as shown in Figure 2. 5hmC was initially detected in
1972 in mammalian DNA [66], but has since been found primarily, and abundantly, in Purkinje
neurons [67], the central nervous system (in the brainstem, spinal cord, and especially the
cerebellum [67] and cerebral cortex) [68], and in embryonic stem (ES) cells [65, 69]. The highest
tissue levels of 5hmC have been consistently found in the brain [69-71]. The striking abundance
of 5hmC in ES cells and PGCs has led scientists to delve into the possibility that 5hmC is linked
with the removal of 5mC in such settings, in vivo. There is evidence to suggest that, unlike
5mC, 5hmC may be correlated with transcriptional activation, after having been found at
euchromatic regions in mice [72, 73]. In essence, while 5mC is known to be a mark of tran‐
scriptional repression, 5hmC may be associated with turning genes back on. Since 2009, a large
quantity of research has been generated, dedicated to studying the potential role of 5hmC in
gene expression regulation. Despite this, we have only just scratched the surface of discovery
as the role of 5hmC in the genome continues to remain highly elusive.
A vital question regarding 5hmC is whether it functions as an intermediate in enzymatic
reactions or as a stable entity unto itself. In this chapter, considerable space will be dedicated
to discussing the possible demethylation pathways in which 5hmC is speculated to be
involved. In this and many contexts, demethylation is defined to be the removal of 5mC and
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(eventual) replacement by cytosine. In the majority of these pathways where 5hmC is required,
it is often thought to act as an intermediate, rapidly replaced by another chemical species.
Levels of 5hmC are substantially lower than 5mC in the genome, at approximately 10% of 5mC
and 0.4% of all cytosines [74]. These minute levels are thought to be consistent with the short-
lived species hypothesis as elevated levels would indicate a longer duration. If 5hmC gener‐
ation is merely a pre-requisite for subsequent demethylation pathways regardless of what form
they take, then 5hmC would be considered a transient species.
Evidence is also emerging which supports the notion of 5hmC as an entirely new landmark in
the epigenetic gene regulatory landscape. In fact, the modified nitrogenous base may even be
responsible for attracting a unique panel of chromatin and transcriptional modifiers. Numer‐
ous mechanisms have been proposed based on preliminary observations. Methyl-CpG binding
domain protein 1 (MBD1) specifically recognizes methylated DNA and attracts histone
deacetylases and H3 lysine 9 methyltransferases (also repressive in action) [75-79]. 5hmC has
CpG islands are regions of the genome that have remained CpG, rather than TpG rich, the latter being the product of
CpG deamination that has taken place over evolutionary time. O/E indicates the ratio of observed CpG sites: expected
number of CpG sites. Strong CGIs tend to have a high O/E meaning that the number of observed CpG sites is approaching
the expected number of CpG sites, making for a maximum O/E of 1. Often unmethylated, these regions of the genome
are associated with transcription start sites. A number of epigenetic patterns have been found to characterize CGIs
(H3K36me2=dimethylation of lysine 36 on histone H3 and H3K4me3=trimethylation of lysine 4 on histone H3).
Table 1. Characteristics of CpG Islands (CGIs)
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been shown to greatly inhibit the binding of these MBDs to DNA [80-82]. On the same note,
DNMT1 is also well known to recruit H3K9 methyltransferases, but the enzyme is blocked by
the very presence of 5hmC, so the likelihood of H3K9 methyltransferase binding is also
reduced. Methylation has also been implicated in nucleosome compaction, making DNA less
accessible to transcription factors [83]. Conversely, the effect of 5hmC on nucleosome com‐
paction has yet to be determined, but the nuclei of Purkinje neurons have been reported to
exhibit marked decondensation [84].
This figure is adapted from Matouk CC, Turgeon PJ, Marsden PA. Epigenetics and stroke risk-beyond the static DNA
code. Advances in Genomics and Genetics. 2012;2012:2:67-84.
Figure 2. Methyl modification to cytosine and hydroxyl addition to 5-methylcytosine. The addition of a methyl group
at the 5-position of cytosine is mediated by the DNA methyltransferase (DNMT) family, where S-adenosylmethionine
serves as the methyl donor. Notes: The ten-eleven translocation (TET) family of enzymes is able to oxidize 5-methylcy‐
tosine to 5-hydroxymethylcytosine in an oxygen-dependent reaction requiring adenosine triphosphate and 2-oxoglu‐
tarate. Cytosine can then be generated from the action of putative demethylases on 5-hydroxymethylcytosine, but has
not yet been fully described.
2.2.4. Ten eleven-translocation (TET) enzymes
The 2009 seminal paper by Tahiliani et al. identified the TET (ten-eleven translocation) enzymes
as being those responsible for the generation of 5hmC by the hydroxylation of 5mC [65].
Adding yet another layer of complexity to uncovering the role of 5hmC in the genome, TET
enzymes are also responsible for the further oxidation of 5hmC into new products: 5-formyl‐
cytosine (5fC) and 5-carboxycytosine (5caC) (70, 85, 86). TET enzymes are present throughout
the Metazoa and the three forms, TET1, TET2, and TET3, are thought to have arisen as a result
of a triplication event that occurred in jawed vertebrates [87]. All three murine forms have
been seen to oxidize 5mC to 5hmC in vitro and in vivo [88, 89]. Moreover, the presence of 5mC
consistently appears to be a pre-requisite for the generation of 5hmC in vivo [69, 72], suggesting
that TET-mediated oxidation is the only means of formation. All of the TET proteins are Fe+2
and 2-oxoglutarate dependent dioxygenases (65, 88, 90). The term, dioxygenase, refers to an
enzyme that catalyzes the addition of both oxygen atoms from molecular oxygen to another
organic substrate. The iron ion is utilized as a co-factor, whereas 2-oxoglutarate is a co-
substrate.
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The mammalian TET enzymes all exhibit a high degree of homology amongst their C terminal
domains. It is the Cys-rich and double stranded-helix DSBH region (CD domain) [87] belong‐
ing to the Cupin-like dioxygenase superfamily, that contains the catalytic domain for 2-
oxoglutarate and iron (II) activity [65, 88]. Further oxidation of 5hmC into 5fC and 5caC also
takes place at this same active site [85]. This CD domain also contains the largest identifiable
portion of the enzyme: the spacer region. For the most part, the function of this region is
unknown, although some leads for future research do exist. For instance, Upabhyay et al. noted
remarkable sequence overlap between the spacer region of TET1 and the C-terminal domain
of RNA polymerase II of S. cerevisiae [91]. Likely of most significance are the conserved residues
that are key sites for posttranslational modifications such as histone methylation and phos‐
phorylation [92]. Located on the N terminus (~60 amino acids) of TET1 and TET3 (not TET2)
enzymes is the CXXC zinc finger domain [65, 87]. Even though its function has not been
conclusively determined, the CXXC domain in TET1 has been shown to bind to unmodified
cytosine, as well as 5mC and 5hmC [93, 94]. Speculation has tended towards this domain
serving as the functional unit responsible for directing the enzymes to particular genomic
regions, almost always CpG sites, so they can execute their oxidative action [92]. A similar
CXXC domain on DNMT1, the enzyme on which it was first discovered, possesses comparable
DNA binding properties [95], initially having suggested an equivalent role for the domain in
TETs.
2.3. Long non-coding RNA
Contrary to the central dogma of biology, in which RNA plays a passive role in transmitting
genetic information to be translated into proteins, recent advances have shown RNA to play
a much more active role in cellular regulation. Long non-coding RNAs (lncRNAs) are the most
recent and least well characterized of functional “non-coding” RNAs. The distinction between
lncRNAs and miRNAs is arbitrary, but has been defined as greater than 200 nucleotides for
an lncRNA [96]. Unlike miRNAs, however, which seem to function through similar pathways,
lncRNAs have been shown to play a diverse assortment of regulatory roles, including
posttranscriptional repression, RNA splicing, and RNA degradation [97]. Despite this variety,
perhaps the most interesting and well-studied mechanism is the ability of many lncRNAs to
act as epigenetic modulators, interacting with chromatin remodeling complexes and other
epigenetic machinery [98].
Xist was one of the first lncRNAs to be discovered [99] and, consequently, is the most well
described. The Xist gene is found in the X chromosome inactivating center (XIC) where it plays
a major role in the inactivation of one of the two X chromosomes in females [100], a process
which equalizes X chromosome dosage to that of a male karyotype. Xist acts in cis to repress
the transcription of the chromosome on which it is transcribed [101]. Xist’s function as an
epigenetic regulator was confirmed with the discovery of an interacting factor, the polycomb
repressive complex 2 (PRC2) [102], a complex that mediates the repressive histone trimethy‐
lation mark H3K27me3. PRC2 is recruited to the inactive X chromosome (Xi) by a short
repetitive sequence, Repeat A (RepA), conserved on the Xist transcript [102]. Tethering of Xist
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to the chromosome from which it was transcribed allows for allele specific recruitment of the
PRC2 complex and subsequent inactivation [101].
Another important lncRNA in X chromosome inactivation is the Xist antisense RNA, Tsix. Tsix
is expressed on the active chromosome and blocks Xist expression, thereby preventing its
inactivation [103]. The action of Tsix illustrates another mechanism of epigenetic regulation in
which lncRNA can take part: DNA methylation. Recently, evidence has suggested that Tsix
mediates DNA methylation at the Xist promoter, silencing the Xist gene [104]. Tsix may
activate DNA methyltransferase 3A (DNMT3A), one of the de novo methyltransferases, and
guide it to the Xist promoter where it is involved in maintaining the silencing of the Xist gene
after initial repression.
X chromosome inactivation is not the only cellular process in which lncRNA is involved, and
there are numerous other examples of lncRNAs as epigenetic regulators. For example,
HOTAIR is an lncRNA located in the homeobox C (HOXC) cluster of genes [105]. The HOX
genes are a family of genes that serve as developmental cues in the embryo [106]. The expres‐
sion pattern of different HOX genes corresponds to specific tissue development and ensures
the correct relative positions of body parts. The 39 HOX genes are present in 4 gene clusters,
HOXA-D, each present on a separate chromosome [107]. HOTAIR is expressed in the HOXC
cluster where it acts in trans to suppress expression on the HOXD cluster. In this way, HOTAIR
is required to maintain the specific expression pattern of HOX genes throughout embryonic
development. Like the Xist RNA, HOTAIR achieves this repression through the recruitment
of the PRC2 complex, which then catalyzes the repressive H3K27 trimethylation mark. Indeed,
knockdown of HOTAIR has shown loss of H3K27 trimethylation in the HOXD gene cluster,
as well as an absence of the PRC2 complex. This suggests that ncRNA may be a global
requirement for activation of PRC2 H3K27me3.
3. DNA methylation and development
Most methylation patterns are stably inherited, remaining static throughout the lifetime of an
organism. Specific cellular processes as well as cell-lineage specificity require activation or
elimination of these patterns. Fluctuations in 5mC and 5hmC levels are most vividly seen in
the cases of pre-implantation development and primordial germ cell formation (Figure 3). In
order to understand the significance of the rapid changes in modified cytosine levels, a number
of recent and vital observations must be taken into account.
a. Pre-implantation embryo
Throughout the duration of development, especially cellular differentiation, somatic-cell
lineages acquire specialized DNA methylation and histone modification patterns. Even in the
earliest stages, both sperm and oocyte are known to contain appreciable levels of DNA
methylation. Many of the methylated regions are shared between oocyte and sperm, such as
intracisternal A particles (IAPs) [108], although there are differentially methylated regions
(DMRs) which is oocyte-or sperm-specific. Active and repressive histone modifications are
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present in the oocyte at this time [109], and it is maternally inherited proteins that will direct
the events of early cleavage divisions. On the other hand, sperm arrive with temporary histone
substitutes, protamines, which play a similarly functional role in packaging [110].
Upon fertilization, the sperm genome is the earliest to undergo major modifications, the first
of which is protamine removal and substitution with histones [111]. Prior to the fusion of the
maternal and paternal pronuclei, a vast genome-wide demethylation event occurs in the
paternal pronucleus [112-115], whereby its methylation patterns are erased almost in their
entirety. This event can occur in as few as six hours following fertilization [112, 113, 116]. This
demethylation has been assessed repeatedly via immunostaining with antibodies specific for
5mC [112, 113, 116] as well as bisulfite sequencing which has clearly shown that one of two
genomes becomes demethylated. A recently discovered and intriguing fact is that this genome-
wide demethylation is actually a mass oxidation event [117-119]. 5mC specific antibodies do
not recognize 5hmC or any other oxidized cytosine, yet it has been repeatedly and conclusively
demonstrated that the male pronucleus does exhibit a marked increase in 5hmC levels at this
time [117-119]. Complimentary antibody staining has taken place in order to deduce this.
Regions unaffected by this event include paternal DMRs in imprinted genes [120, 121] and
IAPs [108]. It is now well known that it is the maternal TET3 enzyme that executes the oxidative
action on the paternal pronucleus [119]. In contrast to the other TET enzymes, TET3 knock‐
down has been demonstrated to result in the near deficit of 5hmC.
The presence of histone modifications unique to the maternal pronucleus is linked to its spared
erasure at this time of otherwise mass oxidation. Developmental pluripotency-associated 3
protein (DPPA3, also known as stella), has been identified as the key protector of the maternal
pronucleus as well as that of a few paternally imprinted genes [122]. As a matter of fact, the
protection offered by this protein is almost indisputable, as experiments have shown that an
absence of DPPA3 results in the hydroxymethylation of both paternal and maternal genomes
[117, 122]. This protein was originally identified as a result of the upregulation of its encoding
gene during initial PGC development [123]. Dimethylation of H3 histone at lysine 9, a mark
that is restricted to these sites [122], has been reported to be responsible for the attraction of
DPPA3 to these regions.
As indicated in Figure 3, the 2-16 cell stage exhibits a substantial decrease in both maternal‐
ly  dominant  5mC and paternally  specific  5hmC levels.  It  is  a  well  known fact  that  the
maternal  genome  also  loses  all  methylation  marks  during  early  embryogenesis.  This,
however, has not been attributed to a mass oxidation event, hence, no generation of 5hmC
takes  place  at  this  time.  The  cytoplasmic  localization  of  DNMT1o,  a  splice  variant  of
DNMT1,  is  attributed to the passive replication-dependent dilution of  all  oxidized cyto‐
sines, [112, 116, 124] accounting also for maternal genome methylation erasure. That is, with
each division, 50% of the genomic methylation and hydroxymethylation patterns are lost
due  to  the  absence  of  maintenance  methylation  [125],  until  virtually  no  modified  cyto‐
sines remain by the sixteen cell stage [112, 116].
Another generally accepted fact is that a wave of de novo methylation takes place at approxi‐
mately the time when the blastula implants into the uterus [116, 120]. This activity occurs very
rapidly and 5mC levels plateau once all of the necessary methylation patterns have been
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instilled (Figure 3). That is, no more demethylation is known to take place because patterns
placed onto the genome at this stage are the same as those that will be found in somatic cells
of later development and maturation. This de novo methylation is now known to be catalyzed
by the de novo methyltransferases 3A and 3B [116]. In fact, inactivation of both DNMT3A and
3B has been shown to result in early embryonic lethality while mutations in the encoding genes
have also resulted in postnatal or embryonic lethality [126, 127]. Establishing the patterns of
the genome at this stage allows for the predictable mitotic transmission of methylation marks
throughout the lifetime of an organism [40].
As opposed to the undoubtedly critical role of TET3 following fertilization in mice, TET1 and
TET2 are thought to have modulatory, yet not essential roles in development, ES cell endur‐
ance, and pluripotency [84]. At the blastula stage, the function of TET1 and TET2 proteins in
the inner cell mass is likely to repress lineage-specific genes, counteracting the effect of
methylation, so as to permit activation of certain genes later in development [128, 129].
Consequently, they are thought to be fine tuning methylation patterns at this point [84].
Consistent experimental results indicate that there is, however, much still to be confirmed
about the relative role of TET proteins in development. As a point of discrepancy, TET1
deficient mouse ES cells have been seen to maintain their self-renewal capabilities in vitro and
develop ordinarily in vivo [130]. Furthermore, numerous groups have demonstrated that the
knockout of both TET1 and TET2 results in the normal development and healthy adulthood
of fertile mice [130-134]. It is hypothesized that such discrepancies may be a result of the
alternate TET proteins compensating for the depletion of one another [92]. Although the
biological roles of TET1 and TET2 in zygotic development are still highly disputable, that of
TET3 appears to be more comprehensive. One study, in particular, highlighted the importance
of this particular enzyme in embryogenesis by introducing a homozygous mutation in the
TET3 encoding gene, subsequently observing neonatal lethality [119]. The same study came
to the conclusion that failure to demethylate the male pronucleus is a direct result of TET3
depletion.
Evidently, epigenetic modifications play an unquestionably enormous role in early develop‐
ment. Despite remaining relatively constant in the mitotic transmission of later development,
methylation patterns undergo rapid, yet precisely timed fluctuations in zygotic development.
5hmC abundance points to a vital role of the TET enzymes, as no other pathway has been
conclusively verified for the generation of hydroxymethylcytosine from methylcytosine. In
light of the recent re-discovery of 5hmC and already substantial amount of scientific inquiry
that has gone into deciphering its role in development, we can hope for a great deal more to
come in the near future!
b. Primordial Germ Cells
Primordial germ cells (PGCs) are the cells that ultimately give rise to the germ line, the oocyte
and sperm. Similar to what has been observed in zygotic development, mouse PGCs, derived
from epiblast cells, are known to experience a correspondingly fast decline in 5mC levels [135]
between embryonic day (E) 9.5 and 13.5 [124, 136, 137]. Very recently, Hackett et al. decisively
demonstrated that the demethylation that takes place in PGCs is conceptually equivalent to
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the mass oxidation event that has been observed during embryonic development. In this case,
TET1 and TET2 are responsible for the generation of 5hmC [124, 138].
Thus far, the acquisition of 5hmC appears to take place between E9.5 and E11.5 [124], but seems
to be lost at a rate that is typical of replication-dependent pattern dilution [124]. Such circum‐
stances closely parallel those seen in zygotic development. In the same way that the DNMT1o
splice variant has been seen to be excluded from the nucleus in zygotic development, UHRF1
consistently appears to be down-regulated in PGC formation [84]. Such a situation prevents
DNMT1 from performing its prescribed action. Evidence indicates that TET-mediated
oxidation in PGCs is likely made possible by passive, rather than active demethylation [124].
This observation is further substantiated by the absence of both 5fC and 5caC following PGC
demethylation, as shown in immunocytochemistry studies [124], whereas their presence in
zygotic development indicates an increased likelihood for an active demethylation mechanism
at work.
By definition, methylation patterns at CpG islands will never be erased during normal
development. Yet, CpG island methylation in the DMR of imprinted genes must undergo
Figure 3. Dynamic nature of 5mC, 5hmC, and TET enzyme levels in the pre-implantation embryo and primordial germ
cell development. Intensity of purple shading indicates the relative level of modified cytosine at that stage in develop‐
ment. Green shading indicates high levels of TET3 activity, while blue shading shows elevated levels of TET1 and TET2
at these stages in development. Sperm and oocyte begin with high levels of 5mC. Paternal methylation patterns are
erased just after fertilization and a mass oxidation event takes place with increasing levels of 5hmC by the zygotic
stage. 5mC and 5hmC (from the paternal genome) levels diminish by means of a passive-replication dependent man‐
ner whereby both the maternal and paternal genomes are practically devoid of either modified cytosine by the 16 cell
stage. Upon implantation in the uterus, mass denovo methylation takes place whereby somatic cell methylation pat‐
terns are established. Primordial germ cells are also subject to demethylation between E9.5 and E13.5, accompanied
by increasing 5hmC levels until approximately E 11. Paternal re-methylation takes place beginning at about E15 and,
in females, after birth.
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erasure so as to ensure that gender-specific methylation associated with imprinting can be put
into place during the remainder of germ cell development [123]. Demethylation at this time
has also been proposed to be responsible for reinstating the pluripotent state in PGCs. Clearly,
those regions whose expression had been repressed are now turned on, allowing for the germ
cell lineage acquisition of pluripotent characteristics, perhaps a pre-requisite to achievement
of totipotency. Similar to the spared erasure of paternally imprinted genes in zygotic devel‐
opment, certain transposons such as IAPs remain moderately methylated at this time [34].
In contrast to zygotic development, the demethylation of imprinted regions is absolutely
critical because germ cells possess imprints that are uniquely exclusive to the gender of the
organism. As indicated in the bottom half of Figure 3, an analogous round of de novo methyl‐
ation also takes place later in oogenesis and spermatogenesis. Re-methylation along with the
re-installation of imprints starts at approximately E15 in males and, in females, after birth [139].
3.1. DNA demethylation pathways
As illustrated above, it is a well ingrained fact that epigenetic reprogramming does take place
in zygotic development and PGC formation. More recently, TET protein activity has been
observed in relation to the timing of particular developmental events. Consequently, levels of
5hmC have been monitored and correlated with the activity of TET proteins at each stage of
interest. Truly novel is the fact that this reprogramming involves a mass oxidation event, that
is, the generation of 5hmC. The function of 5hmC in these stages is a highly debated and
controversial area of research. We have already addressed the first disputed issue regarding
the stability of this oxidized base, but we will now draw our attention to the second debate:
What are the possible demethylation pathways by which reprogramming takes place? We will
define demethylation as the eventual replacement of 5mC with unmodified cytosine. Possible
mechanisms for this can be broadly grouped into passive and active pathways. In analyzing
the possibilities, it is important to note that absolutely no consensus exists as to which
mechanism predominates and that there is experimental evidence to both confirm and rebuke
nearly all pathways.
3.1.1. Passive demethylation
Passive demethylation is fairly well established as one of perhaps several operating processes.
As mentioned above, the maintenance DNMT places methylation patterns on a progeny strand
using the parental strand as a template, similar to the synthesis of a new strand of DNA
whereby DNA polymerase utilizes the parent strand as a template for construction of a
complementarily base-paired DNA strand. Like the DNA double helix, the maintenance of
methylation patterns also occurs through a semi-conservative pathway. This particular setup
yields a hemi-methylated (partly methylated) pattern on the DNA. UHRF1 binding and PCNA
recruitment are the first steps in the faithful copying of methylation patterns from one strand
to another, thereby ensuring the transmission of methylation patterns through mitotic division.
From the perspective of demethylation pathways, if this faithful re-installation of methylation
patterns is disturbed, every generation will subsequently exhibit 50% less methylation.
Eventually, such patterns will undergo what is called passive replication-dependent dilution.
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As mentioned, this appears to be the way in which the methylation patterns of the zygotic
maternal genome are erased. Thus, the plausibility of this mechanism is not debated. Paternal
genome erasure prior to replication is significant evidence that defies the notion of passive
demethylation as the only demethylation pathway.
As far as active or replication-independent pathways go, the central tenets of a variety of these
pathways will be discussed in the following. A common thread that runs beneath a number
of these is the coupling of TET protein activity with a well known DNA repair pathway, base
excision repair (BER), whereby a nitrogenous base is excised by a glycosylase enzyme and
replaced with a new one. Some sort of replacement mechanism is practically inevitable given
that an unmodified cytosine must take the place of a previous base in order to complete
demethylation.
3.1.2. Pathways in which 5fC and 5caC are involved
The first of these proposed pathways involves the other two oxidized bases, 5-formylcytosine
(5fC) and 5-carboxylcytosine (5caC) that can be generated by further oxidation of 5hmC by
TET enzymes [70, 85, 86]. Their presence at very low quantities in the genome (5fC: 0.03% of
5mC in mouse ES cells; 5caC: 0.01% of 5mC in mouse ES cells) [70, 85, 86], has been attributed
to the preference of TET enzymes towards 5mC, not 5hmC, as a substrate, as well as an
exceedingly fast removal of the oxidized bases [85, 140]. Thymine DNA glycosylases (TDGs)
are capable of excising both bases once they are produced. Kinetic studies by Maiti & Drohat
clearly demonstrated that TDG excises 5fC and 5caC, but not 5hmC [141]. Neither when left
for a longer time nor performed at a lower temperature (for enzyme stability maintenance)
was there any significant 5hmC excision [141]. Excision of the oxidized bases opens the door
for base excision repair (BER) action that completes the guanine base on the opposite strand
with a brand new cytosine, hence, completing the demethylation pathway. Several labs have
confirmed that the proposed is a highly plausible mechanism [85, 141, 142].
Interestingly, a number of studies have shown that TDG exhibits strong specificity in its action:
it excises bases which are complementarily base paired with G and/or those which are also
followed by guanine [143-146]. Such an observation is entirely consistent with the proposed
role of TDG and CpG sites [147] whereby the cytosine has undergone a further modification,
yet still fulfills the remainder of the criteria. More research must be undertaken to confirm
whether TDG action on modified cytosines, followed by BER, is a plausible demethylation
mechanism in vivo. Whether such a pathway is of sufficient speed to play a role in demethy‐
lation is one concern which must be addressed. Another comes about when we consider the
exceedingly minute quantities of both of the bases in the genome: How prevalent can this
pathway realistically be? Is it enough to account for mass demethylation in both zygotic and
PGC development?
There is limited evidence that supports a decarboxylation pathway of 5caC, mediated by
proteins present in lysates of ES cells [148]. Although the factors that catalyze this reaction
have yet to be concisely identified, Schiesser et al. utilized isotope tracing to detect the direct
conversion of 5caC to cytosine without interference from BER [148]. The existence of a
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deformylation pathway involved in the direct conversion of 5fC to cytosine has also been
postulated.
3.1.3. Direct removal of 5-methylcytosine
What about a simple removal of the 5mC base followed by TDG action? Scientists have noted
that, due to the strength of the carbon-carbon bond needed to be broken, an enzyme with
unwieldy catalytic power would be needed to achieve such a feat [140]. Methyl-CpG binding
domain protein 2 (MBD2) was first and foremost reported to catalyze just such a reaction. By
its very nature, MBD2 is known to bind to methylated cytosine, so it was often questioned how
it could be responsible for mediating such an active reaction if it first must attach itself [28,
75]. Numerous other downfalls of this theory emerged and no lab was apparently able to
replicate the results, so the theory of MBD2-mediated direct removal of the methyl group of
5mC fell out of favour. Hence, the inevitability of some sort of TDG/BER activity is further
substantiated [149].
A model plant used in genetics and epigenetics studies, Arabidopsis thaliana, is the only source
that has thus far provided evidence for such a direct removal of 5mC (reviewed in [150]). The
existence of ROS1, DME, DML2, and DML7-a family of four 5mC DNA glycosylases has been
acknowledged in this plant [150]. Their preference for acting on 5mC in double stranded DNA,
has led researchers to claim that these enzymes are indeed necessary for active demethylation
of particular genes. The function of these glycosylases is similar to that of BER, in that a nick
created leaves an abasic site which is rapidly repaired. Yet, the enzymes and mechanisms in
mammals appear to be quite distinct from those that have been identified in the plant [151].
3.1.4. AID/APOBEC activity
The second well investigated, yet still highly debated active replication-independent deme‐
thylation pathway is one which also utilizes a DNA repair pathway. AID (activation-induced
cytidine deaminase) and APOBEC (apolipoprotein B mRNA editing enzymes, catalytic
polypeptide) family members are primarily known for their ability to deaminate cytosine to
uracil [152]. In vitro studies have demonstrated the further ability of AID/APOBEC to deami‐
nate 5mC in DNA, to thymine, resulting in a T:G mismatch [149]. The excision conducted by
a TDG glycosylase would subsequently result in an abasic site (apurinic and apyrimidinic [AP]
site) which would then be subject to repair by BER. The final product of such a chain reaction
would be the regeneration of cytosine in place of the modified base [149].
There are a number of variations and caveats of this and related processes. For instance, AID
and APOBEC have frequently been seen to function in a single-stranded DNA environment
[149]. Deamination in single-stranded DNA has been experimentally observed in vitro and in
an E. coli assay [149]. Despite this, AID and APOBEC are both present at appreciable levels in
oocytes as well as PGCs, so their potential role in developmental demethylation has not been
dismissed [149].
An alternate pathway through which AID/APOBEC are thought to function involves the
deamination of 5hmC to 5-hydroxymethyluracil (5hmU) and its subsequent removal by a TDG
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glycosylase or BER pathway [153]. This process would result in the eventual replacement by
cytosine. The over-expression of TET1 and AID have been observed to lead to a global
accumulation of 5hmU [153]. Two potential pathways may compete with one another because
both TDG as well as selective monofunctional uracil-DNA glycosylase 1 (SMUG1) have strong
affinity towards the mismatch that would be generated upon deamination: G:hmU [153, 154].
Hence, one of these mechanisms is thought to play a vital role in mediating the downstream
commencement of BER following 5mC hydroxylation. Such observations substantiate what
many studies propose: that TDG plays an absolutely essential role in active demethylation,
regardless of what mechanism succeeds it.
Perhaps what could be considered the downfall of the AID/APOBEC pathway was elucidated
in a series of experiments and simulations conducted by Nabel et al. [152]. Insisting that the
role of this deamination-based mechanism is limited, the researchers examined the plausibility
of this pathway by investigating the biochemistry of natural and non-natural modified
cytosines. The series of substrates represented a 150 fold difference in reactivity, with the size
of the substituent being an integral determinant of susceptibility to deamination. At one end
of the scale was unmodified cytosine, the behavior of which as a deaminase substrate was
unequivocally superior to all other larger natural and unnatural substrates. The bulky 5hmC
not only sterically hindered the activity of AID/APOBEC, but its poor hydrophobic character
was also implicated in substantially decreasing its reactivity, in comparison to all other bases.
The researchers consolidated their results and firmly stated that AID/APOBEC family
members preferentially deaminate unmodified cytosine, yet strongly discriminate against any
and all 5-substituted cytosine substrates [152]. Clearly, this result contradicts the notion of
5hmC deamination to 5hmU, and more so favours the other possibility of 5mC deamination
to thymine. The hope is that future research will work towards eliminating such discrepancies
amongst multiple lines of work as we gain a better understanding of the plausibility of these
pathways.
3.1.5. DNMT dehydroxymethylation
In addition to AID and APOBEC, the activity of DNMTs themselves has recently been
proposed as a possible 5mC demethylation mechanism. In 2012, Chen et al. demonstrated that
DNMT enzymes can remove the hydroxymethyl group of 5hmC in vitro [155]. Hence, 5hmC
is directly converted to cytosine [156]. Although it is still unknown whether such a reaction
takes place in cells [84], it has been established that reducing conditions favour the generally
accepted methyltransferase activity of DNMT3A and 3B while oxidizing conditions are ideal
for dehydroxymethylation activity [155]. Participation in both methylation and demethylation
results in rapid cycling between the removal and replacement of methylation patterns – a
phenomenon that has been reported in two papers to date [157, 158]. In spite of our analysis
of a limited number of experiments, both papers refer to the interplay of TDG and BER in this
transcriptional cycling. Particular repair proteins were, in fact, recruited to site-specific
locations, likely assisting in the reconstruction of the site [140]. Physiological implications must
also be taken into account. S-adenosylmethionine (SAM) is required, not only at low levels for
the DNMT3A/B mediated reaction, but also at specific levels for other biochemical reactions
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[140]. Scientists continue to ponder the other biological effects which would result from rapid
SAM level fluctuations.
Quite clearly, numerous potential active demethylation pathways do exist and the validity of
one over the other is constantly being reassessed. Further oxidation to 5fC or 5caC, direct
removal of the methyl group, AID/APOBEC, TDG, and BER pathways have all been proposed
and are now under scientific scrutiny. Numerous sources highlight the possibility of more than
one of these pathways operating simultaneously with one or more of the others.
4. Case study I: vitamin C
4.1. Scurvy
Lethargy, extreme muscle and joint pain, gum disease, loosening of teeth, and emotional
instability. Often mistaken for syphilis, leprosy, or dysentery, such were the symptoms that
characterized “the plague of the sea” [159].Now a rare disease, scurvy took the lives of two-
thirds of Vasco de Gama’s men, eighty per cent of Magellan’s mates, and terrorized many of
those who took to the sea during the Age of Exploration. Little did the famed 15th century
explorers know that they were losing members of their crew to a vitamin deficiency. Sailors
who boarded ships destined for long journeys relied mainly on cured and salted meats as well
as dried grains, and suffered greatly for their deprivation of perishable fruits and vegetables.
It was not until its identification and isolation in the 1930s that the association between vitamin
C (ascorbate) and its role in scurvy was made. In fact, ascorbic acid, from which the L-
enantiomer, ascorbate, is derived, actually means “anti-scurvy” [160].
Unlike many animals, primates, humans, guinea pigs, and a few varieties of fish, cannot
synthesize vitamin C de novo in the liver [161]. In humans, for instance, the final step of vitamin
C biosynthesis cannot be performed: the conversion of L-gulono-gamma-lactone into ascorbic
acid. The gene that encodes gulonolactone, the enzyme which catalyzes this reaction, is present
in the human genome, but is inactive as a result of mutation accumulation that turned it into
a pseudogene [162]. Vitamin C is known to be a critical component of health, while lack of it
is truly a detriment to the body because of its dual function in a number of enzymatic reactions
as well as its role as an antioxidant.
4.2. Collagen biosynthesis
Without a doubt, vitamin C presence is absolutely vital in the regular synthesis of collagen.
Being the most abundant protein in mammals and composed mainly of connective tissue [163],
the triple helical construction of collagen requires the successful completion of a number of
biochemical events. One of these is the essential enzymatic hydroxylation of proline (Pro)
residues into hydroxyproline (Hyp) by prolyl-4-hydroxylase (P4H) [164]. A member of a
dioxygenase superfamily, P4H decarboxylates the co-substrate, α-ketoglutarate, and utilizes
Fe2+as a co-factor, yielding hydroxyproline and an oxidized Fe3+[165]. For full catalytic activity,
ascorbate is required as another co-factor in the reaction [166, 167]. In the absence of ascorbate,
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this reaction can perform at a maximal rate, but only to a certain extent [164]. A buildup of
Fe3+requires the activity of ascorbate as a potent reducing agent to regenerate the reduced form
of iron: Fe2+[168, 169]. In this way, the catalytic potential of P4H is maintained at an efficient
level.
Ascorbate deficiency, the situation which arose when sailors went to sea for several months at
a time, leads to the incomplete hydroxylation of proline residues in collagen, which results in
its improper folding [170]. Non-functional collagen in blood vessels and bones has been
attributed to the severe bone and blood vessel related symptoms that came to characterize
scurvy. As a point of interest, the symptoms that extended beyond the changes in bones and
blood vessels, have also been linked to vitamin C deficiency. Prolyl hydroxylases are only one
of a number of enzymes whose mechanism of action relies on this vitamin. The synthesis of
norepinephrine from dopamine, for instance, is catalyzed by dopamine beta hydroxylase,
another enzyme which utilizes vitamin C as a co-factor [171]. Required for the generation of
metabolic energy via mitochondrial breakdown of fatty acids, carnitine synthesis [172], also
necessitates the utilization of ascorbate. Thus, the neurological dysfunctioning of the sailors
and their symptoms of lassitude can both be attributed to a lack of this indispensable vitamin.
Figure 4. Structure of ascorbate. The vital nature of vitamin C (ascorbate) is exemplified by its dual function in the
human body, acting as both a cofactor as well as an antioxidant. Collagen biosynthesis necessitates the hydroxylation
of proline residues by prolyl-4-hydroxylase – one of a number of biochemical reactions that require the presence of
vitamin C. Belonging to the same family as P4H, TET proteins were proposed as possible enzymes whose catalytic ac‐
tion might also have been augmented by the presence of vitamin C. Recent studies have found that ascorbate is re‐
sponsible for widespread, yet specific demethylation, by way of inducing the generation of 5hmC by TET enzymes
Thus far, we have explored an interesting historical event that revealed the enormous impact
of vitamin C on human health. The indisputably important role of vitamin C is further
highlighted by its role in collagen biosynthesis. What’s more intriguing is the fact that prolyl
hydroxylases belong to the same family as the TET enzymes and share numerous structural
features. The possibility of vitamin C interacting with the TET proteins and potentially
contributing to the epigenetic landscape of modifications has become an area of scientific
interest.
A recent report from Minor et al. conclusively stated that ascorbate induces the generation of
5hmC by TET enzymes, likely acting as a co-factor in the reaction [173]. Utilizing mouse
embryonic fibroblasts (MEFs), the addition of ascorbate in a time-and dose-dependent manner
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was unmistakably seen to correlate with increased 5hmC levels. A novel role for vitamin C in
epigenetic modifications has been brought to the forefront. In cells with knocked down TET
expression, ascorbate still enhanced the generation of 5hmC by at least 3 fold above basal levels
[173]. Rather than protein synthesis, it was shown that the mere accumulation of ascorbate
inside the cells was all that was necessary in order to observe increased 5hmC levels. The
researchers noted that a detailed mechanism for ascorbate’s interaction with the TET enzymes
has yet to be elucidated, but the similarity between TET and P4H catalytic action, points
towards ascorbate performing a comparable role in TETs as it does for P4H [173].
Due to its enhancement of cell proliferation, vitamin C is a commonly used medium supple‐
ment in ES cell culture. A Stem Cells report from Chung et al. showed that vitamin C, at the
concentration used in commercial media (50 µg/mL), promotes widespread DNA demethy‐
lation of human ES cells, yet, with remarkable specificity for the location of demethylation
[174]. This study showed that the ascorbate-mediated hypomethylation of CpG island shores
was highly correlated with gene expression at these sites. A precise set of 1,847 genes experi‐
enced altered gene expression as a result of ascorbate addition. From this, researchers specu‐
lated that DNA topology may have been changed such that histone demethylase and acetylase
activity subsequently altered the accessibility of DNA to other factors [174].
Clearly, numerous connections are being made between vitamin C and the epigenetic land‐
scape. Not only does the vitamin act as a co-factor in enzymatic reactions, but its biochemistry
allows it to participate in an even wider array of interactions (Figure 4). As its demethylation
potential is remarkably specific in locale, it was first speculated that this vitamin must be
interacting with other enzymes to execute its action. Indeed, this interaction has been con‐
firmed in the way that TET enzymes are thought to modulate the actual demethylation with
ascorbate acting as a co-factor. Although the exact antioxidant behavior of vitamin C is not
thoroughly illuminated here, the potential role of the general class of antioxidants is revealed
in the context of the pathogenesis of atherosclerosis. Hence, vitamin C is intricately linked with
another underlying theme of this chapter: cardiovascular disease.
4.3. Epigenetic mechanisms and the vascular endothelium
Endothelial cells, those that line the lumen of all blood vessels in mammals, mark the interface
between blood flow and the entrance of substances into tissues and organs. The endothelium,
itself, is composed of a thin layer of endothelial cells and an even thinner layer of basal lamina
beneath the cells. Vascular smooth muscle cells neighbour the endothelial cells, but, as will be
discussed later, exhibit remarkably distinct gene expression. Vasorelaxation was argued, by
Furchgott and Zawadzki, to rely on an intact endothelial lining, from which an endothelium-
derived relaxing factor (EDRF) would be released [175]. Soon after, the EDRF was recognized
to be nitric oxide (NO) [176, 177]. Nitric oxide is now considered to be an incredibly vital
component for maintaining vasculature tone due to its antiatherogenic and antithrombotic
properties [177]. Nitric oxide generation is highly implicated in vasodilation, as well as its
inhibition of platelet aggregation, leukocyte adhesion, and vascular smooth muscle cell
proliferation [178-180].
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A number of biochemical pathways in aerobic cells produce oxygen-derived free radicals as
by-products. Free radicals are molecules with a single unpaired electron, exhibiting great
chemical instability and high reactivity. Donating or accepting an electron normally results in
the generation of another free radical. Normal cellular respiration produces O2-, the superoxide
anion, while the hydroxyl radical OH. is the by-product of the reaction intended to eliminate
O2-. Humans have evolved a number of strategies to combat the production of these reactive
oxygen species (ROS). For this purpose, humans are able to utilize diet-derived or de novo
antioxidants in an effort to convert the damaging species into less toxic substances. Despite
this effort, when the levels of reactive oxygen species are appreciably greater than antioxidant
levels, a condition known as oxidative stress results. Free radicals, which are further generated
from oxidative stress, induce tissue damage and are responsible for detrimental modification
of lipids and proteins in the vasculature.
The damaging impacts of oxidative stress are seen nowhere as vividly as they are in the
endothelium. Endothelial function is impaired by the conditions and NO production is
diminished. The effects are disastrous: reduced vasodilation, enhanced platelet activation, and
increased vascular smooth muscle migration and proliferation [181]. In the way that each of
these outcomes lead to dysfunctioning of the endothelium, all have severe consequences for
the pathogenesis of atherosclerosis. A condition primarily of the intima and a pre-cursor for a
number of severe organismal dysfunctions, atherosclerosis can affect arteries as large as the
aorta or as small as the tertiary branches of coronary arteries [182].
4.4. Pathogenesis of atherosclerosis
The lipid deposition associated with atherosclerosis is derived from an excess of low-density
lipoprotein (LDL), the so-called “bad cholesterol,” in the plasma. Endothelial damage, such
that would occur during oxidative stress conditions, allows for the leakage of LDL into the
sub-endothelial space via LDL receptors in endothelial cells [183, 184]. There, the free radical
and other oxidized agents attack incoming LDL molecules and generate oxidized LDL (ox-
LDL) [184]. Endothelial cells and smooth muscle cells have the capacity to oxidize LDL utilizing
free radicals, the presence of which initiated the oxidative stress conditions [185-187]. Expres‐
sion of adhesive cell surface glycoproteins such as VCAM-1 and ICAM-1 is induced as a result
of mildly oxidized LDL [188-190]. Moreover, a variety of molecules within the intravascular
space are responsible for attracting and modifying monocytes. An environment such as this,
is now rich in modified lipoproteins, chemoattractants, and growth factors, all facilitating the
differentiation of incoming monocytes into macrophages. These macrophages are quite
powerful in that they are capable of a more relentless oxidation of LDL, acting as phagocytes
and promoting smooth muscle cell migration and proliferation [188-191]. These lipid filled
macrophages accumulate rapidly and begin to form the foam cells that characterize an
atherosclerotic lesion on its way to becoming a clinically significant and potentially severe
condition. Because LDL leakage is un-regulated, greater accumulation will lead to the bursting
of the cell and an explosion of free radicals and ox-LDL – an event which upholds the cycling
of cytoxicity, worsening the damage to the endothelium.
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Clearly, the oxidation of LDL exhibits an enormously harmful effect on the endothelium and
drastically alters the dynamics of its cellular function. Hence, endothelial injury and dysfunc‐
tion have been proposed as the initiating events of atherosclerosis. In the presence of cardio‐
vascular risk factors including hyperlipidemia, hypercholesterolemia, smoking, diabetes, and
hypertension, the likelihood of cardiovascular disease is highly augmented.
For quite some time, increased antioxidant intake has been investigated for its potential
biochemical role in reducing the levels of ROS. Antioxidants are known to protect cells from
the effects of free radical damage either by disturbing their mode of production or by attenu‐
ating their proliferation once they have formed. They accomplish the former by converting
free radical reactants into stable species and the latter takes place via neutralizing the effects
of free radical molecules. More precisely, these antioxidants often act by donating an unpaired
electron to the unstable free radical, themselves now in the position of becoming a pro-
oxidative species. Yet, the structure of antioxidants is usually such that their unpaired electron
can be stabilized by adapting one of several possible resonance structures [192-194]. Hence,
antioxidants appear to be a very viable preventative measure towards the onset of atheroscle‐
rosis and potentially subsequent cardiovascular disease. Long-term studies must be conducted
to judge the dose-and time-dependency of the plethora of potential antioxidants. Many of these
substances play several integral roles in the body and any beneficial outcomes may not be a
direct result of a substance’s anti-atherosclerotic properties, per se. Furthermore, atherosclero‐
sis pathogenesis is outstandingly complicated and it is now known that the condition’s
progression is linked to a number of redox-sensitive events that extend beyond the oxidation
of LDL [195]. A great deal more investigation will have to be undertaken in an attempt to
determine which components of the oxidative stress state are critical for atherosclerosis and
the precise mechanism by which antioxidants function.
4.5. Epigenetic regulation of eNOS
Until this point, nitric oxide production and inhibition have been discussed in the context of
atherosclerotic plaque formation and their potential role in cardiovascular disease. Moreover,
from an epigenetic perspective, the endothelium and its biochemical properties also present
an incredibly fascinating model. In mammals, three isoforms of nitric oxide synthase (NOS),
encoded by genes on distinct chromosomes: neuronal NOS (nNOS), inducible NOS (iNOS),
and endothelial NOS (eNOS), are responsible for the production of nitric oxide [196-198]. The
latter of these, eNOS, is known to be the dominant producer of NO and has been found to be
constitutively expressed in the endothelium [199]. The eNOS gene, itself, contains 26 exons
over the length of 21 kb of genomic DNA, maps to chromosome 7q35-36, and is present as a
single copy in the haploid genome [196-198, 200]. Additionally, the gene’s promoter has no
proximal CpG island and a TATA box is also absent [201]. eNOS deficiency, in animals, has
been linked to pulmonary hypertension, atypical vascular remodeling, and flawed angiogen‐
esis [181, 202]. eNOS deficiency in humans has been observed in pulmonary hypertensive
individuals and in the coating of advanced plaques [203]. Much attention has been given to
discovering and documenting the regulation of eNOS in vitro as well as in vivo.
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Transcriptional, posttranscriptional, and posttranslational pathways have been linked to the
intriguing regulation of eNOS [199]. In addition to von Willebrand factor (vWF), vascular-
endothelial cadherin (VE-cadherin), intercellular adhesion molecule-2 (ICAM-2), and the
vascular endothelial growth factor receptors (VEGFR1 and VEGFR2), eNOS is one of many
proteins whose expression is largely endothelial-cell specific [181]. This remarkable nuance
has allowed for gene regulation study, from a predominantly epigenetic perspective.
The classic cis/trans mentality would be the simplest way to account for the endothelial-cell
specificity that is observed in eNOS and the other abovementioned proteins. By this way of
thinking, the cis-acting elements would bind the 5` regulatory regions of target genes in near
proximity. Trans-acting factors would be recruited, but they themselves, would have to be cell-
restricted in expression. This arrangement would describe gene expression regulated by a
master transcription factor. Several well documented instances of master regulation, in
mammalian biology, include NeuroD in neurons [204], smooth muscle cell myocardin [205],
peroxisome proliferator-actived receptor-γ in adipocytes [206], with the most profound
example being MyoD in skeletal muscle cells [207]. In spite of all of these examples, a master
regulator in endothelial cells has yet to be discovered [181]. There are some transcription
factors, such as Hey2, Vezf1, HoxA9 [181], and KLF2 [208] which are preferentially expressed
in the vascular endothelium, but can also be found in other locales. Much research is dedicated
to establishing the prominence of each of these in the vascular endothelium, especially KLF2
(kruppel-like factor 2). Cis-DNA binding elements in the 5`-regulatory regions have been found
in a number of the endothelial-cell restricted genes, and the current train of thought tends
towards the cooperative activity of a unique combination of transcription factors present in
endothelial cells and not in any other cell type [181].
4.6. Role of DNA methylation & eNOS expression
A differentially methylated region (DMR) that had been detected in the proximal promoter of
eNOS in expressing cell types has been observed to be unmethylated or lightly methylated
whereas that same DMR in nonexpressing cell types was heavily methylated [209]. Combina‐
tion of chromatin immunoprecipitation (ChIP) and quantitative real-time PCR revealed the
preferential attraction of transcription factors Sp1, Sp3, and Ets1 to the eNOS proximal
promoter of endothelial cells, even though they were also present in the tested nonexpressing
cell type: vascular smooth muscle cells (VSMC) [209]. Not only did RNA polymerase II
preferentially bind to the proximal promoter of eNOS in endothelial cells, but the transcrip‐
tionally repressive methyl-CpG-binding domain protein, MeCP2, was attracted to the pro‐
moter of VSMCs [210]. Upon treatment with the DNMT inhibitor, 5-azacytidine, those heavily
methylated CpG sites were found to be unmethylated, while expression of the eNOS mRNA
was seen to increase [209]. Hence, human eNOS is the first identified constitutively expressed
vascular endothelium gene whose specificity in expression, is at least partially dictated by
DNA methylation [209].
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4.7. A histone code for the endothelium
Despite the prominence of DNA methylation pathways in these intricate biochemical sequen‐
ces, other chromatin based mechanisms, especially histone posttranslational modifications,
have been studied in the context of eNOS. Transcriptionally activating marks such as the
acetylation of H3 and H4 as well as the di-and tri-methylation of H3K4 have been experimen‐
tally detected in nucleosomes of the eNOS proximal promoter in expressing, but not nonex‐
pressing human cell types [211]. As would be predicted, histone deacetylases (HDAC1 but not
HDAC 2 or 3) were found at the promoter region of nonendothelial cell types [211]. We used
ChIP analysis which recognized, at the eNOS promoter in endothelial cells, the discernible
enrichment of acetylated H3K9 and H4K12. The above observations support the existence of
a histone code unique to the endothelium, whose precise posttranslational modifications are,
to a degree, responsible for gene expression regulation in the endothelium [209, 211].
In summary, current studies are attempting to decipher the relative importance of both DNA
methylation and histone posttranslational modifications in gene expression regulation in the
vascular endothelium. The ways in which these patterns are initially laid down in development
are likely complex and understanding them is still well into the future. It has been speculated
that disturbances of these epigenetic pathways may have implications for human health and
disease. As we have seen, decreased eNOS expression, and hence, reduced NO production,
can have profound consequences for conditions such as atherosclerosis.
4.8. LncRNA and the cardiovascular system
With the traditional four base static genetic code failing to account for the missing heritability
of complex genetic disease phenotypes, the dynamic epigenetic code is becoming widely
accepted as an important determinant of cardiovascular pathologies [212]. Epigenetics
provides a heritable link between our environment and diseases classically linked to genetics.
It should come as no surprise, then, that if lncRNAs can act as epigenetic regulators they might
have a crucial role to play in the development and homeostasis of the cardiovascular system
(Figure 5).
Advances in genome sequencing have allowed for new genetic screening techniques that are
more accurate than ever. Within the last decade, genome wide association studies (GWAS)
have paved the way for understanding genetic variation in common complex diseases. While
traditional family based and linkage analysis studies are effective in identifying rare disease
causing mutations, they fail to uncover genetic variation amongst common diseases such as
cardiovascular disease [213]. Advances in genomic sequencing have lead to the establishment
of databases like the Human Genome Project and the Human Haplotype Map Project that have
allowed GWAS to become a useful and accurate tool for correlating single nucleotide poly‐
morphisms (SNPs) to disease phenotype when implemented correctly. Using microarray
technologies, up to a million SNPs can be assessed.
Interest in cardiovascular epidemiology has led to a number of GWA studies examining
coronary artery disease (CAD) [214]. These studies found an unexpected risk association at
the 9p21 locus, a locus with few protein coding genes. This locus showed the strongest genetic
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correlation to CAD, with ~20-25% of the Caucasian population homozygous for the risk
haplotype corresponding to a 30-40% increase in CAD development [215]. Interestingly,
however, the sequence of a recently described lncRNA, ANRIL (antisense non-coding RNA in
the INK4 locus), was found to overlap with this genomic region [216]. These discoveries put
the spotlight on ANRIL as a new potential regulator of cardiovascular integrity. As such, many
recent studies have shed light on the functions of ANRIL. ANRIL is expressed in endothelial
cells, vascular smooth muscle cells, and leukocytes, all of which are involved in the patho‐
genesis of atherosclerosis [217]. One of the key findings from studies with ANRIL was its
function as an epigenetic regulator of the INK4a/ARF/INK4b locus. This locus encodes three
proteins, p15, p14ARF, and p16, all with important implications as cell cycle regulators, which
together slow cell proliferation. Initiation and maintenance of INK4a/ARF/INK4b gene repres‐
sion is mediated by PRC2 and PRC1, respectively. As demonstrated by Xist and HOTAIR, PRC
complexes seem to have a common relation to lncRNAs. ANRIL is no exception, and interacts
with the SUZ12 subunit of PRC2 and the chromobox 7 (CBX7) subunit of PRC1, recruiting
them in cis to the INK4a/ARF/INK4b locus. Indeed, knockdowns of ANRIL show a decrease
in CBX7 and a subsequent increase in INK4a/ARF/INK4b gene expression. Although the exact
mechanism of ANRIL’s association to cardiovascular diseases has yet to be elucidated, the
preliminary correlation has been made and further work may yet confirm ANRIL as the
important regulatory molecule it is hypothesized to be.
Figure 5. ANRIL is expressed in tissues associated with atherosclerosis. Expression of ANRIL in leukocytes, VSMCs, and
endothelial cells acts in cis to repress the neighboring lNK4a/ARF/lNK4b locus harboring important cell cycle regula‐
tors. Silencing occurs via the recruitment of PRC1 and PRC2 complexes and subsequent increase in the repressive
H3K27me3 histone modification.
More recently, new studies have identified a number of lncRNAs associated with the cardio‐
vascular system. Specifically, two lncRNA have emerged as potential regulators of murine
cardiogenesis. One group of researchers has identified a novel lncRNA, deemed Braveheart
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(Bvht), which plays a role in cardiac development [218]. Bvht is an ~590 nucleotide mouse-
specific transcript that has been shown to be an essential regulator of cardiac commitment in
embryonic stem cells. Knockdown of Bvht in mouse ES cells, which were allowed to differen‐
tiate into cardiomyocytes, showed a substantial decrease in the percent of contractile cells
compared to the control. Although the mechanism is unclear, evidence suggests that Bvht
functions upstream of the MesP1 pathway, a known regulator of cardiac mesoderm develop‐
ment [219]. Notably, Bvht, in agreement with an emerging theme among lncRNAs, was also
shown to interact with PRC complexes [218]. Bvht interacts with the SUZ12 component of the
PRC2 complex. This provides some insight into its function as a possible epigenetic regulator
of cardiac gene expression, although it is not known whether this interaction acts to keep PRC2
from repressing genes needed for cardiogenesis, or if it functions to recruit the repressive
complex to genes that inhibit this process.
Shortly after the discovery of Bvht, another group reported an lncRNA in mice, named Fendrr,
which was similarly involved in the development of the heart [220]. Fendrr is expressed in the
lateral mesoderm of the developing embryo, where it is required for differentiation into lateral
mesoderm derivatives, most notably the cardiac mesoderm and ventral body wall. Accord‐
ingly, Fendrr null mutant embryos are embryonic lethal and display distinct phenotypic
changes in the heart, such as cardiac hypoplasia and impaired function. Once again, epigenetic
regulation by an lncRNA is the likely culprit for these outcomes. Fendrr null mutants show an
increase in the activating H3K4me3 mark, laid down by the TrxG/MLL complex, at the
promoters of the cardiac development regulators GATA6 and Nkx2-5. Co-immunoprecipita‐
tion assays also show an interaction between Fendrr and TrxG/MLL. Additionally, co-
immunoprecipitation assays also show an interaction of Fendrr with TrxG/MLL and PRC2.
Fendrr interacts with the PRC2 complex in both cis and trans to regulate transcription factors
in the lateral and cardiac mesoderm. Fendrr is able to bind to a region near the neighbouring
Foxf1 gene, where it is believed to anchor and guide PRC2 to the promoter region and increase
H3K27me3.
The lncRNAs mentioned are likely only scratching the surface of important regulators of
cardiovascular function. In fact, one recent study using high-throughput sequencing techni‐
ques to study VSMC in rats has identified 24 novel lncRNA differentially expressed in response
to AngII [221]. Similarly, another study has shown, using high throughput RNA-seq techni‐
ques, that 135 non-coding genes show differential expression in failing murine hearts [222].
Together, these studies illustrate the complexity of the cardiovascular transcriptome. With
thousands of putative lncRNAs, more studies will no doubt uncover similar associations to
the cardiovascular system. Further insight into the function of these lncRNAs is crucial to
realizing their contribution to epigenetics, and is a probable direction of many future studies.
4.9. Epigenetic inheritance
A vital component of the definition of epigenetics and one which has briefly been mentioned
in this chapter is that of the heritability of epigenetic patterns. These patterns carry great
significance for the determination and preservation of defined and consistent gene expression
programs that underlie cell fate decisions during and beyond early development. Despite
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flexibility of these patterns in totipotent and pluripotent stages, this plasticity wanes as
development continues. The inheritance of such patterns is, therefore, of the utmost impor‐
tance. The following section will explore the transmission of such information during the
replication stages that take place in mitosis and meiosis, specifically analyzing DNA methyl‐
ation and histone modification patterns within the context of these two processes.
DNA methylation is a significant epigenetic process that nicely fulfills the criterion for
heritability. It has been proposed that DNA methylation may in fact act as a source of epigenetic
memory, via the mitotic pathway. Previously, we offered a widely accepted and elegant
sequence of events to describe the generational inheritance of DNA methylation patterns. De
novo methyltransferases initially place methylation marks on DNA and, following replication,
the maintenance DNMT marks the nascent strand with the same patterns exhibited by the
original parent strand. Quite simply, DNA methylation absence demarcates active promoter
regions, namely CpG islands, such that the promoters in which they are found remain
potentially transcriptionally active throughout development and maturity. Conversely,
segments of the genome that lack promoter activity become methylated and carry the flags of
repression throughout the life of the organism. Our understanding of methylation pattern
inheritance through mitosis is becoming relatively well elucidated, while more studies must
be dedicated to comprehending the ways in which these patterns are initially laid down.
The semi-conservative model of inheritance that applies to both DNA replication and the
transmission of DNA methylation patterns, had been speculated [223], and is now seldom
conceived to be the main mode of transmission of histone modifications. Although compelling,
this model relies on inherent symmetry within mono-nucleosomes as well as the semi-
conservative separation of H3-H4 tetramers [224] (which, together with H2A and H2B dimers,
make up the nucleosome core). Although two copies of each of the core histones are present
within the nucleosome, it is unknown, yet highly doubted, that histone modifications exist in
a symmetric manner [224]. Given the observation that the vast majority of H3-H4 tetramers
actually segregate in a conservative manner [225-228], the more likely candidates to act as
templates for new patterns would actually be adjacent, pre-existing nucleosomes on the same
strand [224]. A possible mechanism for this may be envisioned whereby a neighbouring
nucleosome that will be used as a template, is marked by a chromatin binding protein or reader
protein [229] which would recruit a writer protein. Such a system may act in repetitive
sequences where a number of nucleosomes all require the same replication. A self-cycling
process has been proposed for up keeping repressive H3K27me3 marks, whereby polycomb
repressive complex 2 (PRC2) binds to its own methylation site [230].
Based on these observations, the literal notion of copying a code during the S phase of the cell
cycle does not seem to be applicable to the intricate system of histone modifications. In the
next section, we mention that DNA methylation patterns likely influence the propagation of
histone modifications. It may be speculated that the semi-conservative model applies well to
DNA methylation pattern transmission, and the flags installed on the newly synthesized
strand then act as markers for prompting the appropriate histone modifications.
Histone variant inheritance outside of S phase has suggested that histone modification
inheritance can be replication-independent, unlike the events described above that would
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predominate at the replication fork. Histone variants are altered versions of one of the four
core histone proteins. For example, H3.3 has been shown to be associated with transcriptionally
active segments and is found abundantly in active histone marks [231-233]. H3.3 nucleosomes
are known to be more dynamic and susceptible to displacement during transcription [234].
Consequently, the density of H3.3 nucleosomes is reduced during transcription. The replica‐
tion-independent re-incorporation of H3.3 appears to be mediated by chaperone proteins, such
as HIRA (Hir-related protein A) following the completion of transcription [235, 236]. Hence,
this particular epigenetic modification can be maintained, despite dilution by replication.
4.10. Histone code dispute
Occasionally, the “histone code” is discussed as an entity whose existence is well established,
while, at other times, it proves to be a highly debated topic. In the following, we will briefly
touch upon these disputable characteristics and why a consensus has yet to be reached in this
matter. Numerous tables have been compiled in an attempt to categorize the diverse range of
possible histone modifications and the assortment of amino acid residues that are subject to
these alterations. In contrast to the genetic code, the universality and predictability of the
potential histone code seem to be much less clear-cut. In stark contrast to the genetic code, the
consistency of histone patterns seems to vary dramatically from lower to higher eukaryotes
[237]. Evidence has accumulated which argues against the notion of a simple binary relation‐
ship between modification and effect.
Turner thoroughly reviewed the concept of a histone code, in light of the extensive possibilities
that result from combinations of modification and amino acid, from the perspective of
semiotics: the study of signs and their use or meaning [237]. The genetic code is highlighted
as the quintessential semiotic code in the way that following the central dogma of molecular
biology (DNA→RNA→protein) requires the utilization of symbols, their meaning, and a code
to make known their meaning. Even though the symbols of an epigenetic code would likely
be combinations of histone modifications with DNA methylation marks, the number of these
is far from being known. Such arrangements would increase in quantity with increasing
number of cell types and would have to be pinpointed at different moments in differentiation.
At this point, we can only speculate as to the number of different outcomes based on the
indefinite capacity for combination. Thus, it can be seen that, in order to accurately describe
the transmission of histone modifications as a “code,” a much more comprehensive synthesis
of the variable arrangements must be attained.
4.11. Relationships between epigenetic pathways
Several attempts have been made at identifying the relationships between the discussed
epigenetic pathways. DNA methylation and histone posttranslational modifications have been
implicated in a wide variety of instances, many of which have been discussed in this chapter.
Biochemical and genetic evidence have tended towards a bidirectional relationship between
the two systems: histone methylation has been seen to guide DNA methylation and a DNA
methylation template likely influences the reversible placement of histone modifications [238].
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In the following, both of these options, in addition to the joint roles they play in repression,
will be discussed.
We can now appreciate the dynamic nature of methylation patterns during early development.
At approximately the implantation stage, a wave of de novo methylation inputs the methylation
patterns that will be transferred to somatic cells in subsequent generations. At the same time,
there is a mechanism, speculated to be the combinatorial binding of cis-acting elements and
active demethylation, which serves to protect CpG islands from indiscriminate de novo
methylation (40, 239-241). Interestingly, there is support for the notion that it is the presence
of H3K4 mono-, di-, or tri-methylation that appears to protect CpG islands before the round
of de novo DNA methylation begins (63, 242). Recent studies suggest that H3K4 methylation
protects DNA from de novo methylation [243, 244]. RNA polymerase II is known to be bound
primarily to CpG islands in the early embryo and is responsible for recruiting H3K4 methyl‐
transferases (Table 1) (63, 243-246). Therefore, it is these regions that remain unmethylated as
a result of early histone modifications.
Another significant event of early development occurs at the time of gastrulation when
targeted repression and de novo methylation of pluripotency preserving genes such as Oct3/4,
takes place [247]. A sequential process ensues: binding of repressor molecules with the Oct3/4
promoter turns off transcription [248-250] and a complex containing the histone methyltrans‐
ferase G9a as well as histone deacetylases are recruited. Deacetylation, one of the histone
modifications associated with transcriptional repression, is the next step, resetting the lysine
residues so that G9a is able to catalyze H3K9 methylation [251]. From here, the successive
binding of heterochromatin protein 1 (HP1) facilitates the formation of heterochromatin [251].
Finally, G9a binding also recruits DNMT3A and 3B [252], meaning that the final stages of
silencing are completed. Gastrulation is the time at which the embryo begins to separate into
germ layers, losing the ability to maintain pluripotency. Accordingly, it is histone modifica‐
tions, working in conjunction with DNA methylation pathways that direct the repression of
the expression of pluripotency-associated genes.
In the above two examples, HP1 was discussed in the context of deacetylation, whereas H3K4
methylation was said to protect CpG islands from de novo DNA methylation in early devel‐
opment. There are other instances, however, where H3K4me acts as a binding site for HP1
[253, 254]. A major component of heterochromatin, HP1, is well known to contribute to the
establishment and maintenance of transcriptionally silent heterochromatin [255].
In addition to these instances of histone modifications guiding DNA methylation patterns,
there is evidence to suggest that, through cell division, DNA methylation is important for
maintaining many histone modifications [251]. As discussed previously, DNA methylation
patterns are faithfully transmitted to the next generation by means of the maintenance
methyltransferase DNMT1 and prior UHRF1and PCNA DNA binding. However, despite the
importance of chromatin structure and composition in initiating transcriptional patterns, these
same structures are liable to disruption as the replication fork and associated complexes make
their way along the DNA during replication [251]. It has been inferred that DNA methylation
patterns may act as an important indicator for the reconstruction of epigenetic patterns. That
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is, the more or less accurate transmission is likely necessary for the reproduction of chromatin
conformation after replication has occurred.
Several studies have found that regions rich in unmethylated DNA are reformed in a rather
open conformation, while those regions with more methylated DNA tend to be restructured
in a sealed configuration [256, 257]. Acetylated (activating) histones are the primary compo‐
nent of those unmethylated, open regions. Conversely, it has also been shown that the
nucleosomes of the compact, closed chromatin contain histones which are primarily non-
acetylated [258, 259]. Also worth noting is the fact that methyl-CpG binding domain proteins
such as MeCP2 and MBD2 also demonstrate the ability to attract histone deacetylases to
methylated DNA regions [260, 261]. There is evidence that, in plants, DNA methylation may
inhibit H3K4 methylation, a mark of activation, while perhaps also directing H3K9 dimethy‐
lation, a repressive indicator (259, 262, 263). Thus, even though the mechanism of action may
still be relatively unknown for a number of these hypotheses, evidence does suggest the
potential of a DNA methylation template guiding the placement of histone modifications.
Earlier in this chapter, upon describing the structure of nucleosomes, we mentioned the fact
that ATP-dependent chromatin remodeling complexes often execute an action of nucleosome
sliding. We revisit this topic here, in light of our exploration of the relationships amongst
epigenetic pathways. The regulation of gene expression has also been found to be affected by
these chromatin remodelers, namely the SNF2 family. Containing helical domains but
executing no helicase activity, these proteins disturb the histone/DNA contacts and are
believed to function in both transcriptional activation and repression, depending on the
context [238]. Briefly, we will highlight a few key avenues of research. Jeddeloh et al. were the
first to link DNA methylation with these SNF2 helicases [264]. In A. thaliana, mutation in a
protein called DDM1 (decreased in DNA methylation) resulted in 70% diminishment in global
DNA methylation levels [264]. The mammalian lymphoid specific helicase (Lsh) has been
found to be the most closely related SNF2 member and has been linked to cell proliferation
[238, 265]. Murine knockout experiments have demonstrated normal development until birth,
but death occurs soon after because of renal lesions, as well as defects in lymphoid develop‐
ment and proliferation [238, 266].
Based on the above examples, there certainly seems to be some sort of connectivity between
the epigenetic pathways. Crosstalk is clearly happening between histone posttranslational
modifications and DNA methylation patterns, despite the fact that they are often studied
independently. Future research would certainly focus on deciphering both the direct and
indirect ways in which these processes act in tandem with one another.
5. Case study II: Dutch winter famine
It is a rare and tragic instance when a serious famine strikes an urban and industrialized setting,
but exactly this happened in the winter of 1944-45 in West Netherlands. Excellent documen‐
tation of the event and the people most affected by it has allowed for the study of nutritional
deprivation, in the form of famine, on human reproduction. Under German occupation, the
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Western Netherlands suffered an unusually harsh winter, the effects of which were exacer‐
bated by fuel shortages. Homes were not heated, grass and tulip bulbs were consumed, and
every scrap of furniture was burned in a desperate effort to stay alive [267]. Food rationing
has become an inevitably direct consequence of wartime events, and the Dutch Winter Famine
was no exception to this phenomenon. A 1,800 calorie limit had been upheld for four years
before mid-1944 when it was reduced to 1,600. A stark decline placed the limit at 400 calories
in April of 1945 [267]. Although children as well as expectant and nursing mothers did receive
slightly greater quantities, essentially every person suffered from severe hunger [268].
Case studies dedicated to investigating the impact of malnourished mothers on their offspring
came about as a result of the initial Dutch Famine Birth Cohort Study. There are 2414 singletons
born between November of 1943 and February of 1947 in Amsterdam for whom detailed birth
records were collected and who, at the ages of 50 to 58, were surveyed as to their physical and
mental health [268]. In general, low birth weight has been correlated with a number of
conditions later in life: hypertension, insulin resistance, and obesity [268-271]. A decline in
birth weight of up to 300g was seen among those exposed to maternal malnutrition in the third
trimester [272]. The results of the Cohort study clearly demonstrated that exposure to famine
at any point of gestation was associated with glucose intolerance [273]. Interestingly, the first
trimester proved to be the most decisive stage of gestation at which maternal malnutrition
impacts offspring health. Increased rates of coronary artery disease, atherogenic lipid accu‐
mulation, disturbed blood coagulation, type II diabetes, and cardiovascular disease were
exhibited by those exposed to famine in early gestation. This Cohort Study clearly demon‐
strated that, not only is maternal famine exposure during gestation associated with chronic
disease in offspring later life, but that effects varied based on the timing in gestation of famine
exposure.
How can the solitary existence of the static DNA code account for such remarkable differences
witnessed over the course of a single generation? Changes outside of the genome are needed
to explain this trans-generational variation. To address this issue in more detail, Heijmans et
al. focused on insulin-like growth factor 2 (IGF2), a maternally imprinted gene and a crucial
factor in human growth and development, especially during gestation [274].To investigate
whether maternal famine exposure was associated with differences in methylation of IGF2, 60
periconceptionally exposed people were compared with their same-sex sibling. Overall,
exposure was found to be associated with an average reduction of 5.2% methylation in the
DMR of IGF2. All CpG sites, except for one, were seen to be less methylated in those who had
been exposed [274]. Statistically significant data showed periconceptional exposure, but not
later exposure, was associated with this decrease. It is hypothesized that the deficiency of
methyl donors such as the amino acid methionine, from reduced caloric intake, may account
for the hypomethylation of IGF2 [274]. This study was the first to record persistent epigenetic
changes in response to transient environmental conditions.
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6. Concluding remarks
In this chapter, we have aimed to excite readers about the emerging field of epigenetics and
the potential role it will play in future research initiatives. Without underscoring the impor‐
tance of the genetic code, we have attempted to describe epigenetics in such a way that its
significance is comparatively equivalent to that of genetics. The birth of the current molecular
biological paradigm occurred relatively recently in the history of science, especially the history
of scientific revolutions. Whether or not epigenetics is paving the way for a new paradigm in
biology, is a debate that is best left to the philosophers of science. Yet, the relevancy of
epigenetics cannot be understated as we embark on future investigations into human health
and disease.
Known histone posttranslational modifications were explored first, and the repressive,
activating, or joint consequences of a majority of alterations were delineated. Due to its
duration of study, great emphasis was placed on DNA methylation, its consequences,
mediators, and mechanisms of action. Then, we introduced the re-discovery of the promising
6th base pair: 5hmC. Although its role remains highly elusive, a great deal of research has been
devoted to understanding the demethylation pathways in which this base is likely involved.
Many of these options and their respective caveats were explored in the text. The observations
that have been made about TET enzyme, DNA methylation, and DNA hydroxymethylation
levels in zygotic development and PGC formation were also elucidated in this chapter and
concisely summarized in Figure 3. Long non coding RNAs were discussed in their broad
context as well as the role they play in the cardiovascular system.
Connections across the entire scope of the chapter were highlighted in our exploration of
vitamin C. Its fascinating role in the human body cannot be understated. In scurvy, this
vitamin’s deficiency results in devastating physiological and psychological outcomes. Acting
as both a co-factor for enzymatic reactions and as an antioxidant, the biochemical activity of
ascorbate is also relevant in the context of cell culture and demethylation. Discovering the
connections between P4H and TET enzyme structure has allowed the multi-faceted role of
vitamin C in the epigenome, to also be elucidated. The pathogenesis of atherosclerosis was
mechanized in such a way that the potential role of increased antioxidant intake was high‐
lighted. Epigenetic regulation in the endothelium proves to be dynamic and highly changeable
in the case of cardiovascular disease. eNOS gene regulation was thoroughly investigated as a
representative case of highly endothelial-cell specific expression. Epigenetic inheritance at the
replication fork was addressed in a DNA methylation and histone modification context.
Crosstalk between these two pathways was discussed in the context of both DNA methylation
patterns impacting those of histone modifications and vice versa. Finally, the Dutch Winter
Famine was our second case study, this time further evaluating the role of transgenerational
epigenetic inheritance in the context of severe maternal nutritional deprivation during
pregnancy.
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AID activation-induced cytidine deaminase
APOBEC apolipoprotein B mRNA editing enzymes, catalytic polypeptide
BER base excision repair
ChIP chromatin immunoprecipitation
CD domain Cys-rich and double stranded-helix DSBH region
CpG cytosine - phosphate - guanine
CGIs CpG islands
DPPA3 developmental pluripotency-associated 3 protein
DNMTs DNA methyltransferases
DMR differentially methylated region
ES cell embryonic stem cell
EC endothelial cell
eNOS endothelial nitric oxide synthase
EDRF endothelium-derived relaxing factor
ES cell embryonic stem cell





IGF2 insulin-like growth factor
ICAM-2 intercellular cell adhesion molecule-2
IAPs intracisternal A particles
lnc-RNA long non-coding RNA
MBDs methyl CpG binding domain proteins
miRNA micro RNA
MEFs mouse embryonic fibroblasts
NO nitric oxide
PRC2 polycomb repressive complex 2
PGCs primordial germ cells
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PCNA proliferating cell nuclear antigen
P4H prolyl 4-hydroxylase
ROS reactive oxygen species
SAM S-adenosylmethionine
SMUG1 selective monofunctional uracil-DNA glycosylase 1
SNP single nucleotide polymorphism
SUMO small ubiquitin-like modifier
TET enzymes ten-eleven translocation enzymes
TDG thymine DNA glycosylase
TSS transcription start site
Ub ubiquitin
UHRF1 ubiquitin-like with PHD and ring finger domains 1
VE-cadherin vascular endothelial cadherin
VEGFR vascular endothelial growth factor receptor
VSMC vascular smooth muscle cell
vWF von Willebrand factor
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